Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration

BMC Ophthalmology

Research Article

Doron S. Comaneshter¹  Shlomo Vinker²  Joel Hanhart³  Yossi Freier Dror⁴ 

[1] Central Headquarters, Clalit Health Services, Tel Aviv, Israel;Central Headquarters, Clalit Health Services, Tel Aviv, Israel;Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel;Department of Ophthalmology, Shaare Zedek Medical Center, 12 Beyt Street, 91031, Jerusalem, Israel;Mashav Applied Research, Jerusalem, Israel;

关键词: Neovascular AMD;    Anti-VEGF;    Bevacizumab;    Safety;    Mortality;   

DOI  :  10.1186/s12886-017-0586-0

 received in 2017-02-13, accepted in 2017-10-03,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundThe aim of this study is to analyze mortality in patients treated with bevacizumab for wet AMD.MethodsWe conducted a retrospective case-control study between patients who received intravitreal injections of bevacizumab as the sole treatment for exudative AMD between September 2008 and October 2014 (n = 5385) and age and gender matched controls (n = 10,756). All individuals included in the study were reviewed for sociodemographic data and comorbidities. Survival analysis was performed using adjusted Cox regression, using relevant adjusted variables.ResultsDuring follow-up (maximum: 73 months), 1063 (19.7%) individuals after bevacizumab died compared with 1298 (12.1%) in the control group (P < .001). After adjusted Cox survival regression, mortality differed significantly between the groups, Odds ratio = 1.69, (95% C.I. 1.54–1.84), P < .001.ConclusionsWe found an increased long-term mortality in individuals with wet AMD treated with bevacizumab compared to a same age and gender group without wet AMD.

【 授权许可】

CC BY   
© The Author(s). 2017